secwatch.observer — SEC 8-K summary
======================================

Issuer:     Inhibrx Biosciences, Inc. (INBX)
CIK:        0002007919
Form:       8-K
Filed at:   2026-03-19T23:59:59+00:00
Accession:  0002007919-26-000007
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Inhibrx reports FY2025 net loss $140.1M; cash $124.2M plus $75M debt draw
-------------------------------------------------------------------------

- Net loss FY2025: $140.1M ($9.04/share), vs FY2024 net income $1.7B from 101 Transaction gain.
- Cash $124.2M at Dec 31, 2025; received $75M gross proceeds from Oxford Finance on Mar 18, 2026.
- R&D expense $113M (down 44% YoY); G&A $23.3M (down 82% YoY) due to lower clinical costs and prior-year transaction expenses.
- ozekibart BLA submission for chondrosarcoma expected early Q2 2026; PFS data for CRC expansion Q2 2026.
- INBRX-106: interim ORR data from Phase 2/3 HNSCC trial expected Q2 2026; PFS data at ESMO Q4 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2007919/000200791926000007/0002007919-26-000007-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2007919/000200791926000007/inhibrx-20260319.htm
  HTML page:      https://secwatch.observer/filing/0002007919-26-000007

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer